Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + lenvatinib + XELOX conversion therapy for initially unresectable gastric cancer
ChiCTR2300070798Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, lenvatinib, oxaliplatin and capecitabine in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: R0 surgical conversion rate, R0 resection rate and 5 more. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
sintilimablenvatiniboxaliplatincapecitabine
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2300070798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070798.